Danaher appoints Christopher Riley to Executive Vice President for Biotechnology
Advertisement
Danaher Corporation announced that Christopher Riley has been appointed by its Board of Directors to be Executive Vice President of Danaher with responsibility for its biotechnology business, effective January 1, 2024. Mr. Riley, currently Vice President and Group Executive of Danaher's Life Sciences company with responsibility for Genomic Medicines, will become an executive officer of Danaher reporting to President and Chief Executive Officer, Rainer Blair.
Rainer Blair commented: "Chris' leadership has helped drive the success of our genomic medicines and diagnostics businesses over the past six years. His strong track record of delivering results, passion for helping our customers and building winning teams, plus his deep commitment to the Danaher Business System, is a tremendous asset for Danaher. I look forward to seeing Chris apply his skills and experiences to ensuring the continued success of our Biotechnology business, as we support customers in their pursuit of life-changing breakthroughs for patients."
Mr. Riley joined Danaher in 2007. In his current role, in addition to his Genomic Medicines responsibilities, Chris oversees High Growth Markets and Pall Corporation at Danaher. Previously he was Vice President and Group Executive for Danaher's Diagnostics company and, prior to that, held various roles of increasing responsibility across multiple Danaher subsidiaries. Before joining Danaher, Chris worked for the Boston Consulting Group. He holds a Bachelor of Science degree in Mechanical Engineering from the University of Illinois, as well as a Master of Business Administration degree from Kellogg at Northwestern University.
Other news from the department people
Most read news
More news from our other portals
Last viewed contents
Biotage AB appointment of new CEO
Dr. Christine Munz becomes CEO at Eppendorf - Dr. Wilhelm Plüster completes term in office as planned
Jung Foundation honours cutting-edge research: 4 prizes for medical breakthroughs - Their research has the potential to decisively transform the medicine of tomorrow, or has already done so
Leadership change at Köttermann B.V. in the Netherlands
1.2 million US dollar award honors pioneering work in cryo-electron tomography - Wolfgang Baumeister receives prestigious Shaw Prize
Leon-nanodrugs appoints Dr. Wolfgang Hofmann as Chief Executive Officer
Refeyn Announces Leadership Transition - Jonathan Flint Steps Down as Chairman, Jean-Paul Mangeolle Appointed as Successor
Joachim Kreuzburg, Former CEO of Sartorius, Joins Cube Biotech’s Board of Directors
New high-tech startup developing smart contact lenses for glaucoma diagnosis and management
Insilico Medicine brings AI-powered “ChatPandaGPT” to its target discovery platform - A revolution in drug discovery thanks to a new chat assistant?
Insilico Medicine-led study combines quantum computing and generative AI for drug discovery - “Quantum computing is recognized as the next technology breakthrough which will make a great impact, and the pharmaceutical industry is believed to be among the first wave of industries benefiting from the advancement”
